Overview

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Status:
Terminated
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with gemcitabine and cisplatin chemotherapy. This is a Phase 1b clinical study.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Cisplatin
Gemcitabine
Motesanib diphosphate
Niacinamide
Panitumumab